Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antipsychotic therapy: a pharmacoeconomic perspective.

José A Rey1

  • 1College of Pharmacy, Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, FL 33328, USA. joserey@nova.edu

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|November 29, 2002
PubMed
Summary

Atypical antipsychotics offer better outcomes for schizophrenia patients but have higher upfront costs. Choosing the least expensive atypical option can reduce overall healthcare spending while maintaining treatment effectiveness.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Olanzapine/Samidorphan: A New Option for the Treatment of Adults With Schizophrenia or Bipolar I Disorder.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2022
Same author

Lumateperone: A Novel Antipsychotic for Schizophrenia.

The Annals of pharmacotherapy·2020
Same author

Perseris<sup>TM</sup>: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Intranasal Esketamine (Spravato<sup>TM</sup>) for Use in Treatment-Resistant Depression In Conjunction With an Oral Antidepressant.

P & T : a peer-reviewed journal for formulary management·2019
Same author

Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia.

P & T : a peer-reviewed journal for formulary management·2018
Same author

Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women.

P & T : a peer-reviewed journal for formulary management·2017

Area of Science:

  • Pharmacoeconomics
  • Psychiatry
  • Health Services Research

Background:

  • Schizophrenia is a chronic, early-onset illness with significant long-term healthcare costs.
  • Rehospitalization is a major driver of healthcare expenditures for schizophrenia.
  • Atypical antipsychotics are increasingly used for schizophrenia due to improved efficacy and tolerability over conventional agents.

Purpose of the Study:

  • To discuss the pharmacoeconomics of antipsychotic therapy in schizophrenia.
  • To evaluate the cost-effectiveness of atypical antipsychotics compared to conventional agents.
  • To identify cost-reduction strategies in antipsychotic treatment.

Main Methods:

  • Analysis of antipsychotic therapy within the Veterans Affairs Health System and other healthcare settings.

Related Experiment Videos

  • Comparison of health and economic benefits between atypical and conventional antipsychotics.
  • Examination of acquisition costs and dosage-dependency of atypical antipsychotic drugs.

    • Main Results:

    • Despite higher acquisition costs, atypical antipsychotics provide significant health and economic benefits over conventional agents.
    • The efficacy of various atypical antipsychotics appears to be approximately equivalent.
    • Acquisition costs for atypical antipsychotics vary widely and are often dose-dependent.

    Conclusions:

    • Atypical antipsychotics demonstrate a favorable cost-benefit profile in managing schizophrenia.
    • Selecting the least expensive atypical antipsychotic agent is a viable cost-reduction strategy.
    • Optimizing antipsychotic therapy can lead to substantial healthcare savings and improved patient outcomes.